西班牙纳瓦拉SARS-CoV-2奥密克戎BA.1优势流行期接种疫苗的COVID-19病例住院和重症风险降低
在西班牙纳瓦拉奥密克戎BA.1优势流行期(2022年1月3日至3月20日),对58,952例成人COVID-19病例进行病例对照比较,完全接种疫苗后6个月内住院风险aOR为0.06,6个月后为0.16,加强针后为0.06;重症风险相应aOR分别为0.13、0.18和0.06;与完全接种6个月及以上者相比,加强针后住院和重症风险aOR均为0.38。
要点
- 完全接种后6个月内住院风险aOR 0.06,6个月后aOR 0.16,加强针后aOR 0.06。
- 重症风险在完全接种6个月内aOR 0.13,6个月后aOR 0.18,加强针后aOR 0.06。
- 与完全接种6个月及以上者相比,加强针后住院和重症风险aOR均为0.38。
核心结论
- 完全接种COVID-19疫苗大幅降低奥密克戎变异株感染病例的住院和重症风险,加强针在65岁以上人群中改善此效果。
研究设计与样本
- 病例对照比较,纳入2022年1月3日至3月20日西班牙纳瓦拉≥18岁成人COVID-19流行病学监测数据,共58,952例COVID-19病例。
主要发现
- 58,952例COVID-19病例中,565例(1.0%)住院,156例(0.3%)为重症。
- 完全接种后6个月内住院风险aOR为0.06(95%CI:0.04-0.09),6个月后aOR为0.16(95%CI:0.12-0.21;组间比较P<0.001),加强针后aOR为0.06(95%CI:0.04-0.07)。
- 重症风险相应aOR分别为0.13、0.18和0.06。
- 与完全接种6个月及以上者相比,加强针后住院风险aOR为0.38(95%CI:0.28-0.52),重症风险aOR为0.38(95%CI:0.21-0.68)。
临床怎么用
- 完全接种COVID-19疫苗可降低奥密克戎变异株感染病例的住院和重症风险,加强针在65岁以上人群中改善此效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BackgroundAs COVID-19 vaccine effectiveness against SARS-CoV-2 infection was lower for cases of the Omicron vs the Delta variant, understanding the effect of vaccination in reducing risk of hospitalisation and severe disease among COVID-19 cases is crucial.AimTo evaluate risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the Omicron BA.1-predominant period in Navarre, Spain.MethodsA case-to-case comparison included COVID-19 epidemiological surveillance data in adults ≥ 18 years from 3 January-20 March 2022. COVID-19 vaccination status was compared between hospitalised and non-hospitalised cases, and between severe (intensive care unit admission or death) and non-severe cases using logistic regression models.ResultsAmong 58,952 COVID-19 cases, 565 (1.0%) were hospitalised and 156 (0.3%) were severe. The risk of hospitalisation was reduced within the first 6 months after full COVID-19 vaccination (complete primary series) (adjusted odds ratio (aOR): 0.06; 95% CI: 0.04-0.09) and after 6 months (aOR: 0.16; 95% CI: 0.12-0.21; pcomparison < 0.001), as well as after a booster dose (aOR: 0.06: 95% CI: 0.04-0.07). Similarly, the risk of severe disease was reduced (aOR: 0.13, 0.18, and 0.06, respectively). Compared with cases fully vaccinated 6 months or more before a positive test, those who had received a booster dose had lower risk of hospitalisation (aOR: 0.38; 95% CI: 0.28-0.52) and severe disease (aOR: 0.38; 95% CI: 0.21-0.68).ConclusionsFull COVID-19 vaccination greatly reduced the risk of hospitalisation and severe outcomes in COVID-19 cases with the Omicron variant, and a booster dose improved this effect in people aged over 65 years.
引用
- Martínez-Baz I, Trobajo-Sanmartín C, Miqueleiz A, et al. Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022. Euro Surveill. 2023. PMID: 36729113. doi:10.2807/1560-7917.ES.2023.28.5.2200337
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。